DailyIQ
Last updatedUpdating…

BIIB·Biogen Inc.

$232.68
+3.78 (+1.65%)
High
$233.90
Open
$229.25
Market Cap
33.83B
52W High
$238.24
Low
$228.00
P. Close
$232.68
P/E
40.53
52W Low
$138.00
Fwd P/E
13.84
DailyIQ Est.
$253.63
Inst. Ownership
52.2%
Short Interest
4.05%
Days to Cover
4.9
Technical Score (1D)
83
BULLISH
News Sentiment
48
MIXED
On Oct 13, Biogen was scheduled to release its Q3 earnings. Analysts had forecasted a sharp double‑digit decline in earnings per share, citing projected revenue shortfalls and higher operating costs. The forecast was widely cited in market commentary, suggesting a material negative impact on the company’s financial outlook. The anticipation of this decline was noted by analysts and investors alike. The report highlighted the challenges the company faces in meeting revenue targets. The forecast was expected to influence perceptions of Biogen’s future performance.
LOW TARGET
$175 -24.8%
2 analysts
MEAN TARGET
$244 +4.9%
24 analysts
HIGH TARGET
$300 +28.9%
18 analysts
PRICE RANGE
$175.00 - $300.00
SB / B / H / S / SS
10/20/12/1/1
DAILYIQ EST.
$253.63 (+9.0%)
Sector
Healthcare
Industry
Drug Manufacturers - General
Exchange
NMS
Country
United States
Website
Symbol
BIIB
Description
Biogen Inc. is a global biotechnology company focused on discovering and delivering therapies for neurological and neurodegenerative diseases. The company's core business revolves around developing treatments for multiple sclerosis, spinal muscular atrophy, and other conditions like Friedreich's Ataxia and amyotrophic lateral sclerosis. Biogen's portfolio includes established brands such as TECFIDERA and TYSABRI, as well as biosimilars targeting rheumatoid arthritis and certain lymphomas. Furthermore, Biogen actively engages in research and development to expand its pipeline, exploring potential treatments for Alzheimer's disease, Parkinson's disease, and other neurological disorders, often through collaborations with other biopharmaceutical companies. Headquartered in Cambridge, Massachusetts, Biogen aims to address unmet medical needs within the challenging field of neuroscience.
Bought (1Y)
0 shares
$0
Sold (1Y)
1,194 shares
$242K
Godbout SeanChief Accounting Officer
Option Exercise27 shares2026-10-02
Godbout SeanChief Accounting Officer
Tax Withholding8 shares2026-10-02
Godbout SeanChief Accounting Officer
Option Exercise27 shares2026-10-02
Godbout SeanChief Accounting Officer
Award/Grant985 shares2026-10-01
Parini MichaelChief Legal Officer
Award/Grant7,405 shares2026-09-01
72/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
75.7%
Net Margin
13.1%
Revenue CAGR
6.5%
Current Ratio
2.68x
Debt / Equity
0.34x
Return on Equity
7.1%
Earnings Summary
Biogen Inc. is a global biotechnology firm headquartered in Cambridge, Massachusetts, focused on developing therapies for neurological and neurodegenerative diseases such as multiple sclerosis, spinal muscular atrophy, and amyotrophic lateral sclerosis, with a portfolio that includes TECFIDERA and TYSABRI and biosimilar products for rheumatoid arthritis and lymphomas. In the drug manufacturers sector, Biogen operates in a highly competitive, research‑intensive environment where pipeline development and regulatory approvals drive long‑term growth. Recent quarterly performance shows a mixed trajectory: Q4 2024 EPS of $3.44 beat the $3.3639 estimate while revenue of $2.4547 billion exceeded expectations; Q1 2025 EPS of $3.02 surpassed the $2.94824 estimate with revenue of $2.431 billion; Q2 2025 EPS surged to $5.47 against a $3.88017 estimate, and revenue rose to $2.6455 billion; Q3 2025 EPS of $4.81 beat the $3.88288 estimate with revenue of $2.5347 billion; Q4 2025 EPS of $1.99 outperformed the $1.626 estimate and revenue of $2.2794 billion exceeded the $2.248 billion estimate; Q1 2026 EPS of $3.57 beat the $2.95216 estimate and revenue of $2.4778 billion surpassed the $2.247 billion estimate; Q2 2026 EPS of $3.6 exceeded the $2.02954 estimate and revenue of $2.736 billion outpaced the $2.503 billion estimate. This pattern of EPS beats in seven of the last eight quarters, coupled with revenue growth in six quarters, underscores Biogen’s ability to maintain profitability despite market pressures. Historically, the company has shown a YoY revenue growth trajectory that has generally outpaced EPS growth, with notable beats in Q2 2025 and Q1 2026, while occasional misses in Q4 2025 EPS reflect the impact of higher operating costs. Recent news highlights a modest RBC price target cut to $256 on Oct 8, reflecting a slightly more conservative near‑term earnings view, and analyst expectations of a modest EPS beat in Q3 2026, suggesting continued confidence in the company’s earnings resilience.

EPS

EstBeatMiss
$1.05$2.30$3.55$4.80$6.05Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.02 - -
Q2'26$2.03$3.60+77.4%
Q1'26$2.95$3.57+20.9%
Q4'25$1.63$1.99+22.4%
Q3'25$3.88$4.81+23.9%
Q2'25$3.88$5.47+41.0%

Revenue

EstBeatMiss
$2.2B$2.3B$2.5B$2.7B$2.8BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$2.7B - -
Q2'26$2.5B$2.7B+9.3%
Q1'26$2.2B$2.5B+10.2%
Q4'25$2.2B$2.3B+1.4%
Q3'25 - $2.5B -
Q2'25 - $2.6B -

Market Data

BIIB Stock Snapshot

BULLISH83/100
$232.68+$3.78 (1.7%)
Market cap
33.83B
P/E ratio
40.5
Day range
$228.00 – $233.90
News sentiment
48/100 · Neutral
Analyst target
$243.98 (+4.9%)
Consensus
Buy · 44 analysts
52-week range+68.6% off low · -2.3% from high
$138.00$238.24
Price $232.68 DailyIQ Est. $253.63

BIIB is trading with the trend behind it, which is what pushes the technical read bullish. In Healthcare, names this size usually take direction from sector flows before company-level news.

Reverse DCF

What growth is priced into BIIB?

CHEAP

At today's price, Biogen Inc. needs to grow free cash flow about 0.5% a year for the next 10 years to justify its valuation at a 7.72% cost of capital. Over its actual history it has compounded free cash flow at 5.1% a year, so the market is asking for 4.6 percentage points below its own delivered rate. On that basis BIIB looks priced below what its own growth record supports.

Implied FCF growth
0.5%
Historical FCF CAGR
5.1%
Growth gap
-4.6 pts
Verdict
CHEAP
Discount rate (WACC)
7.72%
Beta
0.65

Behaviour On Record

What BIIB's own history says about today's numbers

Realized volatility (21d)
22.4% 23rd pct
Below its peak
-47.1%
vs 200-day average
+16.5%
Up days (1y)
53%

Biogen Inc. is currently running 22.4% annualised volatility over the last 21 sessions. Measured against BIIB's own 13 years of daily returns rather than a market-wide average, that is the 23rd percentile — unusually subdued by its own history, against a typical reading of 29.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

BIIB is trading -47.1% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -31.0%, and the deepest was -46.2% in 2021. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +16.5% from its 200-day moving average. Against every other day in its history, that gap ranks at the 85th percentile — a wider gap than this stock usually carries. Over the past year BIIB closed higher on 53% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 14 years of records, BIIB finished the month higher 5 of 14 times, with a median return of -1.7% and an average of -1.1%. Its strongest month historically has been November at +2.1% on average, its weakest March at -4.7%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: BIIB has opened more than 2% away from the prior close in 109 of 3,267 sessions (3.3% of the time), with the largest gaps running +5.7% and -30.7%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, BIIB moved an average of 3.1% in the session after earnings, closing higher 0 of those 3 times, with a median move of -3.6% and a largest of -3.8%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against BIIB's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of BIIB's sector?

Biogen Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for BIIB?

CallsPuts

For Biogen Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.69), with at-the-money implied volatility around 40.6%. The options market is pricing roughly a ±3.6% move by that expiry — a range of about $224.43–$241.25.

Put/call ratio (2026-10-16)
0.69
ATM implied volatility
40.6%
Total open interest
6,072
Expected move by 2026-10-16
±3.6% ($224.43–$241.25)

Analyst Rating Changes

Are analysts turning bullish or bearish on BIIB?

JP Morgan most recently upgraded Biogen Inc. to Overweight on Oct 12, 2026 with a price target of $300 (from $210). Over the last 90 days, coverage has run 2 upgrades against 0 downgrades, a net bullish lean.

Latest action
JP Morgan — Overweight
90-day upgrades
2
90-day downgrades
0
Net rating momentum
+2
DateFirmActionRatingPrice target
Oct 12, 2026JP MorganUpgradeNeutral → Overweight$210 → $300
Oct 9, 2026UBSMaintainedBuy$240 → $270
Oct 8, 2026RBC CapitalMaintainedOutperform$260 → $256
Sep 10, 2026HSBCMaintainedReduce$165 → $175
Sep 3, 2026Piper SandlerReiteratedOverweight$225 → $245
Aug 25, 2026RBC CapitalMaintainedOutperform$240 → $260
Aug 13, 2026Wolfe ResearchUpgradePeer Perform → Outperform$300
Aug 4, 2026MizuhoMaintainedOutperform$221 → $241
Aug 3, 2026CitigroupMaintainedNeutral$200 → $215
Jul 30, 2026UBSMaintainedBuy$225 → $240
Jul 30, 2026HC Wainwright & Co.MaintainedBuy$237 → $251
Jul 30, 2026Morgan StanleyMaintainedEqual-Weight$222 → $231

Peers & ETF holders

BIIB peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

48/100
Strong NegativeNeutralStrong Positive
MIXED

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Biogen was set to report its Q3 results on October 13, with analysts forecasting a sharp double‑digit decline in earnings per share. The forecast was based on projected revenue shortfalls and higher operating costs. The expectation of a significant earnings drop was widely cited in market commentary, suggesting a material negative impact on the company’s financial outlook.
What did this article say?
Biogen’s share price has rebounded significantly over the past year, yet analysts question whether the current valuation reflects the company’s realistic cash‑generation potential. The article highlights that the stock could be trading 49% below fair value, driven by uncertainty surrounding upcoming lupus trial results. This valuation gap suggests that investors may be overestimating the company’s near‑term financial performance. The piece underscores the need for caution as the market remains sensitive to clinical data releases. Overall, the narrative presents a moderate negative outlook for Biogen’s stock.
What did this article say?
UBS analyst Michael Yee upgraded Biogen (BIIB) to a Buy rating and increased the price target from $240 to $270. The upgrade reflects confidence in the company’s pipeline and recent clinical progress. The new target suggests a potential upside for investors based on UBS’s valuation assumptions. The move is expected to support market sentiment toward Biogen’s growth prospects.
What did this article say?
RBC reduced its price target for Biogen (BIIB) from $260 to $256, citing a more conservative view of the company's near‑term earnings. The bank retained an outperform rating, indicating it still sees upside potential. The adjustment reflects a modest reassessment of Biogen’s valuation relative to peers. The change may influence investor expectations for the upcoming earnings cycle. Overall, the move signals a slight headwind for the stock without a drastic shift in outlook.
What did this article say?
RBC Capital analyst Brian Abrahams lowered Biogen’s (NASDAQ:BIIB) price target from $260 to $256 while keeping an Outperform rating. The adjustment reflects a modest view that the company’s valuation is slightly overextended relative to its earnings outlook. The downgrade in target price signals a cautious stance on Biogen’s near‑term growth prospects. The rating remains positive, indicating that RBC still expects the company to outperform the broader market. The change is likely to influence short‑term investor sentiment and trading activity.
What did this article say?
Biogen Inc. (BIIB) was projected to report a modest earnings per share beat in its third‑quarter results, with analysts forecasting $2.14 versus a consensus of $2.07. Revenue was expected to hold steady at approximately $2.6 billion. The guidance was driven by expectations that lower cost of goods sold and research and development expenses would offset the impact of the upcoming lupus trial data. The company’s financial outlook remained largely unchanged, with no significant shift in strategic direction. The forecast reflects a mild positive tailwind for the company’s earnings outlook.
What did this article say?
Biogen Inc. (BIIB) reported earnings of $3.60 per share for the most recent quarter, exceeding the consensus estimate of $3.04 by 18.42%. The company’s average earnings surprise over the last two quarters was 19.72%, reinforcing its track record of beating expectations. Analysts highlighted the positive Earnings ESP and strong Zacks Rank as indicators that the earnings beat streak may persist. The consistent outperformance supports investor confidence in Biogen’s financial health and management execution. No material guidance changes or adverse events were disclosed in the report.
What did this article say?
Biogen reported that litifilimab achieved sustained efficacy over 52 weeks in the Phase 2/3 AMETHYST study for cutaneous lupus erythematosus. The proportion of patients with clear or almost clear skin rose from 27.2% at week 24 to 28.8% at week 52, while disease activity scores improved accordingly. Early responders who switched from placebo saw skin improvements within four weeks, indicating rapid onset. These results reinforce litifilimab’s potential as a first‑class therapy and may support future regulatory submissions.

Technical Analysis

Real-time indicators across multiple timeframes

83
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $15.83B combined position · 14 adding, 11 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
FMR LLC (Fidelity)▲ Buy18,217,23912.36%$3.94B2026-08-13
BlackRock, Inc.▲ Buy15,985,73610.84%$3.45B2026-08-07
Vanguard Group Inc▲ Buy17,447,09211.84%$3.07B2026-01-29
Geode Capital Management, LLC▲ Buy4,449,2953.02%$957.94M2026-08-12
Wellington Management Group LLP▲ Buy3,117,4692.11%$673.56M2026-08-14
Norges Bank▼ Sell2,580,0331.75%$557.44M2026-08-12
Morgan Stanley▲ Buy2,411,2711.64%$520.98M2026-08-13
AQR Capital Management LLC▲ Buy1,936,8591.31%$416.93M2026-08-14
JPMorgan Chase & Co▼ Sell1,823,1401.24%$394.95M2026-08-12
Invesco Ltd.▲ Buy1,803,9441.22%$389.76M2026-08-14
Northern Trust Corp▼ Sell1,429,4900.97%$308.86M2026-08-13
Goldman Sachs Group Inc▲ Buy1,230,3900.83%$265.84M2026-08-14
Bank of America Corp▼ Sell1,116,2280.76%$241.17M2026-08-14
Citigroup Inc▲ Buy734,5170.50%$158.70M2026-08-03
Citadel Advisors LLC▲ Buy418,3560.28%$90.39M2026-09-02
Fisher Asset Management, LLC▲ Buy338,0180.23%$73.03M2026-08-04
Gotham Asset Management, LLC▼ Sell279,9000.19%$60.48M2026-08-14
Balyasny Asset Management L.P.▼ Sell265,0900.18%$57.28M2026-08-14
Man Group plc▼ Sell196,2220.13%$42.40M2026-08-14
AllianceBernstein L.P.▲ Buy214,9750.15%$39.41M2026-08-14
Palo Alto Investors LP▼ Sell140,2790.10%$30.31M2026-08-19
Adage Capital Partners GP, L.L.C.▼ Sell129,5990.09%$28.00M2026-08-14
Wells Fargo & Company▲ Buy128,6640.09%$27.80M2026-08-14
Point72 Asset Management, L.P.▼ Sell88,1490.06%$19.05M2026-08-14
Renaissance Technologies LLC▼ Sell77,7440.05%$16.80M2026-08-13
Q2 2026 flow:6.72M sh bought ($1.45B)1.89M sh sold ($407.67M)net +4.83M sh (+$1.04B)
Congressional Trading Activity
23 disclosed trades · ~$257.5K est. traded value · 13 buys, 10 sells
MemberChamberStateTypeAmountTradedFiled
Maria Elvira SalazarHouseFL27▼ Sell$1K - $15K2026-09-242026-10-07
Kevin HernHouseOK01▼ Sell$1K - $15K2026-08-182026-09-01
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-06-052026-07-02
Maria Elvira SalazarHouseFL27▼ Sell$15K - $50K2026-06-022026-07-07
Maria Elvira SalazarHouseFL27▲ Buy$1K - $15K2026-05-122026-06-08
Maria Elvira SalazarHouseFL27▲ Buy$1K - $15K2026-05-112026-06-08
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-01-302026-02-13
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-05-152025-06-09
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-04-082025-05-08
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2019-03-222019-04-17
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2018-01-082018-02-13
Sheldon WhitehouseSenateRI▼ Sell$1K - $15K2016-12-232017-01-11
Sheldon WhitehouseSenateRI▼ Sell$15K - $50K2016-12-132017-01-11
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2015-08-282015-09-24
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2015-08-102016-08-11
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2015-08-042016-08-11
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2015-07-102015-07-21
Sheldon WhitehouseSenateRI▲ Buy$15K - $50K2015-05-072015-08-12
Sheldon WhitehouseSenateRI▲ Buy$1K - $15K2015-04-072015-04-23
Susan M. CollinsSenateME▼ Sell$1K - $15K2014-07-232015-07-20
Susan M. CollinsSenateME▼ Sell$1K - $15K2014-03-272014-04-01